126 related articles for article (PubMed ID: 36842413)
1. Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation.
Weppler AM; Da Meda L; Pires da Silva I; Xu W; Grignani G; Menzies AM; Carlino MS; Long GV; Lo SN; Nordman I; Steer CB; Lyle M; Trojaniello C; Ascierto PA; Lebbe C; Sandhu S
Eur J Cancer; 2023 Apr; 183():109-118. PubMed ID: 36842413
[TBL] [Abstract][Full Text] [Related]
2. Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study.
Stege HM; Haist M; Schultheis S; Fleischer MI; Mohr P; Ugurel S; Terheyden P; Thiem A; Kiecker F; Leiter U; Becker JC; Meissner M; Kleeman J; Pföhler C; Hassel J; Grabbe S; Loquai C
Cancer Immunol Immunother; 2021 Nov; 70(11):3313-3322. PubMed ID: 33870464
[TBL] [Abstract][Full Text] [Related]
3. Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma.
Nghiem P; Bhatia S; Lipson EJ; Sharfman WH; Kudchadkar RR; Brohl AS; Friedlander PA; Daud A; Kluger HM; Reddy SA; Boulmay BC; Riker A; Burgess MA; Hanks BA; Olencki T; Kendra K; Church C; Akaike T; Ramchurren N; Shinohara MM; Salim B; Taube JM; Jensen E; Kalabis M; Fling SP; Homet Moreno B; Sharon E; Cheever MA; Topalian SL
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33879601
[TBL] [Abstract][Full Text] [Related]
4. Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial.
D'Angelo SP; Bhatia S; Brohl AS; Hamid O; Mehnert JM; Terheyden P; Shih KC; Brownell I; Lebbé C; Lewis KD; Linette GP; Milella M; Georges S; Shah P; Ellers-Lenz B; Bajars M; Güzel G; Nghiem PT
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32414862
[TBL] [Abstract][Full Text] [Related]
5. Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial.
Kaufman HL; Russell JS; Hamid O; Bhatia S; Terheyden P; D'Angelo SP; Shih KC; Lebbé C; Milella M; Brownell I; Lewis KD; Lorch JH; von Heydebreck A; Hennessy M; Nghiem P
J Immunother Cancer; 2018 Jan; 6(1):7. PubMed ID: 29347993
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11).
Kim H; Kim DW; Kim M; Lee Y; Ahn HK; Cho JH; Kim IH; Lee YG; Shin SH; Park SE; Jung J; Kang EJ; Ahn MJ
Cancer; 2022 Feb; 128(4):778-787. PubMed ID: 34705268
[TBL] [Abstract][Full Text] [Related]
7. Avelumab treatment for patients with metastatic Merkel cell carcinoma can be safely stopped after 1 year and a PET/CT-confirmed complete response.
Zijlker LP; Levy S; Wolters W; van Thienen JV; van Akkooi ACJ; Tesselaar MET
Cancer; 2024 Feb; 130(3):433-438. PubMed ID: 37788133
[TBL] [Abstract][Full Text] [Related]
8. Clinical, FDG-PET and molecular markers of immune checkpoint inhibitor response in patients with metastatic Merkel cell carcinoma.
Weppler AM; Pattison A; Bhave P; De Ieso P; Raleigh J; Hatzimihalis A; Gill AJ; Balachander S; Callahan J; Chua M; Au-Yeung G; McArthur GA; Hicks RJ; Tothill RW; Sandhu S
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33060145
[TBL] [Abstract][Full Text] [Related]
9. Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with advanced non-small cell lung cancer (NSCLC): INTEPI, a multicentric retrospective study.
Bilger G; Girard N; Doubre H; Levra MG; Giroux-Leprieur E; Giraud F; Decroisette C; Carton M; Massiani MA
Cancer Immunol Immunother; 2022 Jul; 71(7):1719-1731. PubMed ID: 34821950
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial.
D'Angelo SP; Russell J; Lebbé C; Chmielowski B; Gambichler T; Grob JJ; Kiecker F; Rabinowits G; Terheyden P; Zwiener I; Bajars M; Hennessy M; Kaufman HL
JAMA Oncol; 2018 Sep; 4(9):e180077. PubMed ID: 29566106
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of responders to PD-1/PD-L1 inhibitors who discontinue therapy after sustained disease control.
Sharma H; Moturi KR; Pankratz VS; Yilmaz E; Gbolahan OB; Kumar A; Hashemi-Sadraei N
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8673-8680. PubMed ID: 37115270
[TBL] [Abstract][Full Text] [Related]
12. Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up.
D'Angelo SP; Bhatia S; Brohl AS; Hamid O; Mehnert JM; Terheyden P; Shih KC; Brownell I; Lebbé C; Lewis KD; Linette GP; Milella M; Xiong H; Guezel G; Nghiem PT
ESMO Open; 2021 Dec; 6(6):100290. PubMed ID: 34715570
[TBL] [Abstract][Full Text] [Related]
13. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
14. Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma.
Iyer JG; Blom A; Doumani R; Lewis C; Tarabadkar ES; Anderson A; Ma C; Bestick A; Parvathaneni U; Bhatia S; Nghiem P
Cancer Med; 2016 Sep; 5(9):2294-301. PubMed ID: 27431483
[TBL] [Abstract][Full Text] [Related]
15. Real-world experience with elective discontinuation of PD-1 inhibitors at 1 year in patients with metastatic melanoma.
Pokorny R; McPherson JP; Haaland B; Grossmann KF; Luckett C; Voorhies BN; Sageser DS; Wallentine J; Tolman Z; Hu-Lieskovan S; Swami U
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33500258
[TBL] [Abstract][Full Text] [Related]
16. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
17. Exploring long-term responses to immune checkpoint inhibitors in recurrent and metastatic head and neck squamous cell carcinoma.
Bila M; Franken A; Van Dessel J; Garip M; Meulemans J; Willaert R; Hoeben A; Vander Poorten V; Clement PM
Oral Oncol; 2024 Feb; 149():106664. PubMed ID: 38113661
[TBL] [Abstract][Full Text] [Related]
18. Real-World Clinical Outcomes in Patients with Locally Advanced or Metastatic Merkel Cell Carcinoma Treated in U.S. Oncology Clinical Practices: Results from SPEAR-Merkel.
Bhanegaonkar A; Liu FX; Boyd M; Fulcher N; Kim R; Krulewicz S; Smith J; Cowey CL
Oncologist; 2021 Sep; 26(9):e1633-e1643. PubMed ID: 34101298
[TBL] [Abstract][Full Text] [Related]
19. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
20. Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG.
Glutsch V; Schummer P; Kneitz H; Gesierich A; Goebeler M; Klein D; Posch C; Gebhardt C; Haferkamp S; Zimmer L; Becker JC; Leiter U; Weichenthal M; Schadendorf D; Ugurel S; Schilling B
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36450381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
